Remove Bioavailability Remove FDA Approval Remove Life Science
article thumbnail

PureTech Reveals New CBD Pill to Rival Jazz’s Epidiolex

XTalks

Clinical-stage biotech company PureTech Health has announced it has developed a new oral CBD therapeutic candidate with improved bioavailability and tolerability, which could expand use of the CBD prodrug in a wide range of indications and age groups. PureTech said this could potentially mean improved safety and reduced side effects.

article thumbnail

Orserdu (elacestrant) Approved for Patients with ESR1 mutations in ER+/HER2- Advanced or Metastatic Breast Cancers

XTalks

Until now, fulvestrant was the only other selective estrogen receptor degrader (SERD) therapy approved for ER+ breast cancer, delivered via intramuscular injections. “Advanced or metastatic ER+, HER2- breast cancer pre-treated with endocrine-based therapy remains an area of unmet medical need.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Vevye: A New Cyclosporine Solution for Dry Eye Disease

XTalks

Furthermore, the bioavailability of the active pharmaceutical ingredient (API) into the cornea is up to four times stronger with EyeSol technology. One such approved medication is Miebo , an ophthalmic solution developed by Bausch + Lomb and Novaliq.

article thumbnail

Considerations for Neuroscience Trials with Intrathecal Delivery and Other Methods of Direct CNS Administration

XTalks

A major obstacle for CNS drug developers is the inability to target therapies to the CNS broadly (for instance, a therapy that is orally bioavailable as a pill and has difficulty crossing the blood-brain barrier) and certain CNS regions more specifically. Direct CNS administration is also FDA-approved for multiple small molecules and ASOs.

Trials 83
article thumbnail

Advances in Oncology Clinical Trials and Hematology: The Impact of BTK Inhibitors

XTalks

It was engineered to have high potency, bioavailability and kinase selectivity that led to improved efficacy and safety in B-cell malignancies. Zanubrutinib has five US Food and Drug Administration (FDA)-approved indications and the broadest label in its class.

article thumbnail

Novartis’ Fabhalta (Iptacopan) Earns Third FDA Nod, This Time for C3G

XTalks

Without effective disease-modifying therapies and optimal management strategies, the constant fatigue, swelling and mental health challenges surrounding those living with C3G profoundly disrupt daily life and overall quality of life.